|Bid||0.0000 x 1800|
|Ask||0.0000 x 1300|
|Day's Range||2.4500 - 2.6200|
|52 Week Range||2.4500 - 25.1700|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019 after market close. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 3264026.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
If you own shares in Nuvectra Corporation (NASDAQ:NVTR) then it's worth thinking about how it contributes to the...
PLANO, Texas, June 12, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that members of management are scheduled to.
Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MR-conditional approval for the Company’s Algovita SCS system. Fred Parks, Chief Executive Officer, commented, “We believe full-body MR-conditional approval in the United States, in addition to Algovita’s full-body MR-conditional CE Mark approval, will supplement our existing competitive advantages and expand the number of eligible patients. This submission, pending regulatory approval from the FDA, would position the Company to achieve MR-conditional approval at or around year end 2019 following a 180-day review process.
Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today preliminary Algovita® clinical data from its U.S. and EU multi-center, single-arm study demonstrating lead fracture and migration rates that were below industry average. The study data was presented by Robert Levy, MD, PhD, a board-certified neurological surgeon and member of Nuvectra’s Medical Advisory Board, at the International Neuromodulation Society (INS) 14th Annual World Congress in Sydney, Australia. The preliminary results are based on clinical outcomes for 75 patients up to approximately 7 months following permanent implantation at 18 clinical sites.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced that Walter Z. Berger has resigned as Nuvectra’s Chief Operating Officer and Chief Financial Officer to pursue another business opportunity, effective May 24, 2019. The Board of Directors accepted Mr. Berger’s resignation and has appointed Ms. Jennifer Kosharek, the Company’s current Vice President, Controller and Principal Accounting Officer, as interim Chief Financial Officer as it initiates a search for a successor.
Nuvectra (NVTR) delivered earnings and revenue surprises of -27.69% and -12.79%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Plano, Texas-based company said it had a loss of 83 cents per share. The medical device company posted revenue of $11.1 million in the period, which did not meet Street forecasts. Three analysts surveyed ...
PLANO, Texas, May 01, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended.
NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Nuvectra Corp. (NASDAQ: NVTR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 1, 2019 at 4:30 PM Eastern Time. ...
Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLANO, Texas, April 22, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Nuvectra Corporation (NASDAQ:NVTR) shareholders, and potential investors, need to understand how much cash the business makes...
Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have ...
Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A. Miller’s retirement from the Board, effective immediately. Concurrently, Jane J. Song was appointed as an independent member of the Company’s Board of Directors and as a member of the Board’s Governance and Nomination Committee. Mr. Bihl stated, “I am honored to enter my new role as Chairman of the Board and welcome Jane, an industry leader, to Nuvectra.
Nuvectra Corp (NASDAQ:NVTR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
PLANO, Texas, Feb. 28, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full.
While small-cap stocks, such as Nuvectra Corporation (NASDAQ:NVTR) with its market cap of US$246m, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
PLANO, Texas, Feb. 26, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer,.